中国癌症杂志 ›› 2015, Vol. 25 ›› Issue (1): 38-44.doi: 10.3969/j.issn.1007-3969.2015.01.007

• 论著 • 上一篇    下一篇

白头翁皂苷B4、粉防己碱对奥沙利铂耐药的结肠癌细胞的耐药逆转作用及其机制

李敏,方明治   

  1. 南京市中医院肿瘤科, 江苏 南京 210001
  • 出版日期:2015-01-30 发布日期:2015-05-08
  • 通信作者: 方明治 E-mail:fangmingzhi@medmail.com.cn
  • 基金资助:
    南京市医学科技发展青年启动项目(QYK11135)。

Resistance reverse effect of anemoside B4 and tetrandrine on oxaliplatin-resistant human colon cancer cells and the mechanism

LI Min, FANG Mingzhi   

  1. Department of Oncology, Nanjing Hospital of Traditional Chinese Medicine, Nanjing Jiangsu 210001, China
  • Published:2015-01-30 Online:2015-05-08
  • Contact: FANG Mingzhi E-mail: fangmingzhi@medmail.com.cn

摘要:
背景与目的:奥沙利铂(oraliplatin,L-OHP)是结直肠癌最常用的化疗药物之一,但临床上常见结直肠癌L-OHP化疗耐药。本研究旨在探讨中药单体白头翁皂苷B4(anemoside B4,AB4)以及粉防己碱(Tetrandrine,Tet)对人结肠癌L-OHP耐药细胞LoVo/L-OHP耐药的逆转作用,并初步研究其机制。方法:采用浓度梯度实验筛选无毒剂量的AB4、Tet,无毒剂量的AB4、Tet作用于LoVo/L-OHP细胞48 h后,检测LoVo/L-OHP细胞对L-OHP耐药的变化,检测处理后细胞凋亡、细胞周期变化情况,通过RT-PCR及Western blot检测相关基因P-gp、zDHHC9和SMAD4的mRNA及蛋白的表达水平。结果:AB4及Tet作用48 h后对LoVo/L-OHP细胞的5%抑制率浓度分别为0.71及0.45 μg/mL,以此作为无毒剂量。L-OHP对LoVo/L-OHP细胞IC50为(112.5±23.6)μg/mL,分别加入0.71 μg/mL AB4及0.45 μg/mL Tet后,L-OHP对LoVo/L-OHP细胞的IC50值分别为 (62.8±21.4)及(58.9±26.3) μg/mL,IC50值均显著下降(P值均<0.05)。细胞周期检测发现,AB4及Tet处理后G1期细胞略有减少,S期细胞略有增加,但差异无统计学意义(P>0.05)。细胞凋亡检测发现AB4及Tet处理后凋亡率略有上升,但差异均无统计学意义(P>0.05)。RT-PCR检测显示耐药细胞相对于亲本细胞,P-gp及zDHHC9基因表达升高,SMAD4表达降低(P值均<0.05),经过AB4处理后,耐药细胞P-gp基因表达下降。Western blot检测相关蛋白水平后发现,耐药细胞经过AB4处理后,P-gp蛋白表达下降,经过Tet处理后zDHHC9蛋白表达下调。结论:AB4及Tet能逆转LoVo/L-OHP耐药细胞对L-OHP的耐药,AB4逆转机制可能与降低P-gp表达有关,Tet逆转机制与降低zDHHC9表达水平有关。

关键词:  结直肠癌, 化疗耐药, 奥沙利铂, 白头翁皂苷B4, 粉防己碱

Abstract:
Background and purpose: Oxaliplatin (L-OHP) is one of the most commonly used chemotherapy drugs in colorectal cancer and L-OHP-resistance is very common in colorectal cancer therapy. This research was to discuss the reversal effect in L-OHP-resistant human colon cancer cell line LoVo/L-OHP by anemoside B4 (AB4) and tetrandrine (Tet) and to clarify their molecular mechanism. Methods: LoVo/L-OHP cells were treated for 48 h by AB4 and Tet at different concentrations to get non-toxic dose. Drug sensitivity was measured by MTT. After the treatment, the cell cycle and apoptosis of the cells were detected. Expression of P-gp mRNA, zDHHC9 mRNA and SMAD4 mRNA were detected by RT-PCR. Expression of P-gp, zDHHC9 and SMAD4 protein were detected by Western blot. Results: The IC50 of LoVo/L-OHP for L-OHP was (112.5±23.6) μg/mL, and the IC50 decreased to (62.8±21.4) μg/mL (P<0.05) and (58.9±26.3) μg/mL (P<0.05) after the treatment with 0.71 μg/mL AB4 and 0.45 μg/mL Tet (non-toxic dose) separately. The cell cycle experiment showed that the cells in G1 stage decreased and in S stage increased but with no statistical significance (P>0.05). The cell apoptosis experiment showed that the apoptotic rate increased after the treatment with AB4 and Tet with non-toxic dose but with no statistical significance (P>0.05). The RT-PCR experiment showed that the expressions of P-gp mRNA and zDHHC9 mRNA were increased and SMAD4 mRNA was decreased in LoVo/L-OHP cells compared with in LoVo cells (P<0.05), while it was found that P-gp mRNA in LoVo/L-OHP cells was decreased after the treatment with AB4 at non-toxic dose (P<0.05). Western blot experiment showed the protein of P-gp in LoVo/L-OHP cells was decreased after treatment with AB4 (P<0.05), which was accordant to the PCR result. The expression of zDHHC9 protein in LoVo/L-OHP cells was decreased in LoVo/L-OHP cells after treatment with Tet (P<0.05). Conclusion: AB4 and Tet have some reversal effect on resistant to L-OHP in LoVo/L-OHP cells. The molecular mechanism of the resistance reverse effect was related to down-regulation of P-gp for AB4 and down-regulation of zDHHC9 for Tet.

Key words: Colorectal cancer, Chemo-resistance, Oxaliplatin, Anemoside B4, Tetrandrine